Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > Prostate Cancer: A Change in… >
Prostate Cancer: A Change in Circulating Tumor Cells Detection Has High Potential in the Prediction

Published: October 11, 2013.
By European Association of Urology
http://www.uroweb.org

Arnhem, 11 October 2013- A new study reveals that in the prediction of treatment outcome for castration-resistant prostate cancer, a change in circulating tumour cells detection might be more accurate than the change in prostate-specific antigen levels. The findings of this award-winning study were presented at the recent EAU 13th Central European Meeting in Prague.

"The research of the circulating tumour cells (CTC) is of utmost importance, because nowadays there is no reliable marker of both cancer-specific or overall survival in castration-resistant prostate cancer (CRPC) patients," explained the lead author of the study, Dr. Otakar Čapoun, of the Department of Urology at General Teaching Hospital Charles University in Prague, Czech Republic.

"The goal of this study is to assess the possibility of the individualisation of castration-resistant prostate cancer management. In cases with no favourable change in CTC detection during chemotherapy, the early switching to another therapy should be considered," commented Čapoun on the implications of the study, which was supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic.

Protocol of the grant project included the collection of peripheral blood from patients with metastatic CRPC prior to docetaxel therapy and after the fourth cycle of chemotherapy (CTX). Circulating tumour cells were detected by using a method of immunomagnetic separation. In the course of the study multiplex-PCR was performed after cytolysis of CTC and the expression of tumour-associated antigens (PSA, PSMA and EGFR) was quantified.

The methodology of the study was based on verbal evaluation together with a report of the absolute values (ng/ml). The authors recorded the levels of serum PSA (sPSA) and the fragments of respective antigens before and in the course of CTX and compared the values. They also evaluated the correlation between the change of sPSA and expression of CTC antigens during CTX.

The study included 26 patients with both samples taken in 17 of them. Median age was 72 years (54-82), mean sPSA level before and after CTX was 197.6 and 120.1ng/ml, respectively. Before CTX only 2 out of 26 patients were considered CTC negative, whereas during the CTX the CTC negativity was confirmed in 9 out of 17 cases. Before CTX, positive detection of fragments of antigens for PSA, PSMA and EGFR was confirmed in 23, 16 and 2 patients, respectively, and during CTX in 8, 3 and 1 case, respectively. The sPSA level before CTX was associated with the level of fragments for PSA (p=0.0020) and PSMA (p=00.0147). During CTX the association was seen in all antigens. However neither a change in sPSA level nor a change in positive versus negative CTC statement correlated with a change of any of the tested antigens.

The study concludes that the sPSA level has the most accurate correlation with the level of gene fragment for PSA in CTC. A favourable change in CTC quantity will occur in more than a half of patients during chemotherapy, however the change in CTC detection does not correlate with the change of the sPSA level.

"This research project is divided into several arms, among others, we are investigating the feasibility of CTC cultivation and genetic profiling," commented Čapoun referring to the possibility of follow-up research.

"This gene profile will be compared with primary tumour at the time of diagnosis. In the future, this CTC profiling might be useful for even more accurate and better tailored selection of treatment for castration-resistant prostate cancer."


Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Patients 
10/5/11 
New Tool Helps Identify Prostate Cancer Patients with Highest Risk of Death
By Fox Chase Cancer Center
After a prostate cancer patient receives radiation treatment, his doctor carefully monitors the amount of prostate-specific antigen, or PSA, in his blood. An increase in PSA, called biochemical failure, …
Buyyounouski 
11/2/10 
Prognostic Markers for Prostate Cancer Patients Who Receive Radiation After Surgery
By Fox Chase Cancer Center
SAN DIEGO, CA (November 3, 2010)—Removal of the prostate gland often eradicates early-stage cancer. But patients whose cancer has spread may need to follow up with what is known …
Cancer 
4/1/12 
Tokai Pharmaceuticals' Galeterone Well-tolerated in Patients with Advanced Prostate Cancer
By Pure Communications Inc.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and …
Tasquinimod 
11/19/13 
Oral Drug May Improve Survival in Men with Metastatic Prostate Cancer
By Duke University Medical Center
DURHAM, N.C. – An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis …
Treatment 
11/16/11 
Denosumab Delays Development of Prostate Cancer Bone Metastasis
By Massachusetts General Hospital
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate …
Peptide 
3/15/13 
Japanese P2 Study Shows Potential of Combined Vaccine And Steroid Drug in Castration-resistant PCa
By European Association of Urology
Arnhem, 11 March 2013- Multi-peptide vaccination therapy combined with the low-dose steroid drug dexamethasone shows promise in treating chemotherapy-naive castration resistant prostate cancer (CRPC) patients. …
Biomarker 
8/12/10 
The Cancer Biomarker Conundrum: Too Many False Discoveries
By Journal of the National Cancer Institute
The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition